Laura Chico, an analyst from Wedbush, maintained the Buy rating on Viridian Therapeutics. The associated price target was raised to $47.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Laura Chico’s rating is based on several promising factors regarding Viridian Therapeutics. The company has been added to the Wedbush Best Ideas List due to its strong performance and potential for further growth as key data events approach. The upcoming VRDN-003 Phase 3 REVEAL studies and the potential approval of veligrotug in the latter half of 2026 are seen as significant catalysts that could drive the stock higher.
Additionally, Viridian’s robust cash position, which supports its operations through profitability, and the reduction in the discount rate from 25% to 20% reflect increased confidence in the company’s execution and future prospects. The potential for veligrotug to capture market share with its shorter treatment duration compared to competitors, along with the promising pipeline of VRDN-003, positions Viridian well for competitive strength. These factors combined justify the Buy rating and the increased price target of $47, with the potential for further upside if commercial uptake exceeds expectations.
In another report released on December 3, William Blair also initiated coverage with a Buy rating on the stock with a $47.00 price target.